Precigen
Yahoo Finance • 7 days ago
Vertex Posts Positive Phase II Data on Kidney Disease Drug
Vertex Pharmaceuticals VRTX announced positive data from the phase IIb AMPLIFIED study, which evaluated its investigational drug, inaxaplin, for the treatment of patients with APOL1-mediated kidney disease ("AMKD") and modest proteinuria a... Full story
Yahoo Finance • 7 days ago
AstraZeneca's Trixeo Secures Approval for Asthma in the EU
AstraZeneca AZN announced that the European Commission has approved its respiratory drug, Trixeo Aerosphere, for a new indication. The drug is approved in the European Union (EU) as a maintenance treatment for previously treated asthma pa... Full story
Yahoo Finance • 8 days ago
AbbVie's Rinvoq Wins EU Approval in Juvenile Idiopathic Arthritis
AbbVie ABBV announced that the European Commission ("EC") has approved its blockbuster immunology drug, Rinvoq (upadacitinib), for a new indication. The drug is approved in the European Union for the treatment of active polyarticular juven... Full story
Yahoo Finance • 8 days ago
Alkermes Posts Positive Data From Phase I ADHD Study on ALKS 7290
Alkermes ALKS announced positive top-line data from a phase I proof-of-concept study evaluating its novel, investigational orexin 2 receptor (OX2R) agonist, ALKS 7290, for the treatment of attention-deficit hyperactivity disorder (ADHD).... Full story
Yahoo Finance • 8 days ago
JNJ's Caplyta Shows Benefit in Bipolar 1 Related Mania Study
Johnson & Johnson JNJ announced positive top-line data from a pivotal phase III study evaluating Caplyta (lumateperone) for treating manic episodes, with or without mixed features, in adults with bipolar I disorder. More on JNJ's Latest S... Full story
Yahoo Finance • 9 days ago
AZN's Klygefa Gets CHMP Nod for Generalised Myasthenia Gravis in EU
AstraZeneca AZN announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has issued a positive opinion recommending the approval of its rare-disease drug, Klygefa (gefurulimab), as an add-on... Full story
Yahoo Finance • 9 days ago
Merck Gets CHMP Backing for Keytruda-Padcev Combo in Bladder Cancer
Merck MRK announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use ("CHMP") has issued a positive opinion recommending approval of a combination of its blockbuster PD-L1 inhibitor, Keytruda (pembr... Full story
Yahoo Finance • 9 days ago
CHMP Backs CORT's Lifyorli Combo in Platinum-Resistant Ovarian Cancer
Corcept Therapeutics CORT announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of Lifyorli (relacorilant) in combination with nab-pac... Full story
Yahoo Finance • 9 days ago
Novo's Sogroya Gains CHMP Nod for Idiopathic Short Stature in the EU
Novo NVO announced that its once-weekly growth hormone therapy Sogroya (somapacitan) received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) for treating children with idiopath... Full story
Yahoo Finance • 12 days ago
Novo's Denecimig Gets CHMP Nod for Hemophilia A in the European Union
Novo NVO announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has issued a positive opinion recommending the approval of denecimig (Mim8) for the treatment of hemophilia A, with or witho... Full story
Yahoo Finance • 13 days ago
Novo Expands AI Push With Anthropic Deal to Accelerate Drug Discovery
Novo NVO is expanding its artificial intelligence (AI) capabilities through a new collaboration with Anthropic to accelerate drug discovery and development of new medicines. Under the agreement, Novo will use Anthropic's models and Claude... Full story
Yahoo Finance • 15 days ago
Immunocore Hits Enrollment Target in Kimmtrak Label Expansion Study
Immunocore IMCR announced that it has achieved target enrollment of 540 patients in the phase III TEBE-AM study, which is evaluating its sole marketed drug, Kimmtrak (tebentafusp), in patients with second-line or later advanced melanoma.... Full story
Yahoo Finance • 17 days ago
Precigen Gains 43% in 3 Months: Is It an Indication to Buy the Stock?
Shares of Precigen PGEN have rallied 42.7% in the past three months. This stock price rally can be attributed to growing investor confidence in the strong commercial performance of the company's sole marketed drug, Papzimeos (zopapogene im... Full story
Yahoo Finance • 20 days ago
AbbVie's Atogepant Meets Goal in Late-Stage Menstrual Migraine Study
AbbVie ABBV announced positive top-line data from the phase III LUNA study, which evaluated atogepant, an oral calcitonin gene-related peptide receptor antagonist, for preventive treatment of menstrual migraine in adult women. Menstrual mi... Full story
Yahoo Finance • 20 days ago
Bayer Secures FDA Nod for Sevabertinib's First-Line Use in NSCLC
Bayer BAYRY announced that the FDA has granted approval to sevabertinib through an accelerated pathway for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors have... Full story
Yahoo Finance • 20 days ago
Roche Gets FDA Priority Tag for Enspryng in Rare Autoimmune Disorder
Roche RHHBY announced that the FDA has accepted its supplemental biologics license application (sBLA) seeking approval of Enspryng (satralizumab) for the treatment of myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD).... Full story
Yahoo Finance • 20 days ago
Can Papzimeos Drive Precigen's Growth Through the Rest of 2026?
Precigen PGEN is making steady progress on the back of strong commercial performance from its sole marketed drug Papzimeos (zopapogene imadenovec-drba). The product remains a key top-line driver for the company. Papzimeos is currently the... Full story
Yahoo Finance • 26 days ago
ABBV's Etentamig Meets Goals in Phase III Multiple Myeloma Study
AbbVie ABBV reported positive top-line data from the phase III CERVINO study, evaluating its investigational pipeline candidate, etentamig, in certain patients with relapsed/refractory multiple myeloma (RRMM) who had received prior treatme... Full story
Yahoo Finance • 29 days ago
AZN's Tagrisso Plus Orpathys Study in First-Line NSCLC Meets Goal
AstraZeneca AZN announced positive data from the phase III SANOVO study evaluating Tagrisso (osimertinib) plus Orpathys (savolitinib) in treatment-naïve patients with EGFR-mutated advanced or metastatic non-small cell lung cancer (NSCLC) w... Full story
Yahoo Finance • last month
Here's Why You Should Add ACET Stock to Your Portfolio Now
Adicet Bio ACET continues to make steady progress with prula-cel/prulacabtagene leucel (formerly known as ADI-001),the company's lead product candidate and primary clinical value driver in autoimmune diseases. It is a first-in-class invest... Full story